One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Assessing enthesitis using ultrasound: unfinished business
Diogo Esperança Almeida, Richard J Wakefield
doi : 10.1093/rheumatology/keac380
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4581–4582
Quantitative chest imaging and prediction of mortality in rheumatoid arthritis–associated interstitial lung disease
Gregory McDermott, Jeffrey A Sparks
doi : 10.1093/rheumatology/keac329
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4583–4584
Anti-topoisomerase-positive limited systemic sclerosis has a propensity for interstitial lung disease but is linked to favourable prognosis
Ruhani P Desai, Shervin Assassi
doi : 10.1093/rheumatology/keac287
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4585–4586
The role of PET/CT in the evaluation of patients with large-vessel vasculitis: useful for diagnosis but with potential limitations for follow-up
Miguel A González-Gay, Diana Prieto-Peña, Santos Castañeda
doi : 10.1093/rheumatology/keac251
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4587–4589
Musculoskeletal ultrasound for treating rheumatoid arthritis to target—a systematic literature review
Ettore Silvagni, Sara Zandonella Callegher, Eleonora Mauric, Sofia Chiricolo, Nikolaus Schreiber, Annarita Tullio, Alen Zabotti, Carlo Alberto Scirè, Christian Dejaco, Garifallia Sakellariou
doi : 10.1093/rheumatology/keac261
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4590–4602
We aimed to systematically review the literature to retrieve evidence on the diagnostic and prognostic value of musculoskeletal ultrasound for a treat to target (T2T) approach in RA.
Psychometric properties of outcome measurement instruments for ANCA-associated vasculitis: a systematic literature review
Alvise Berti, Gonçalo Boleto, Peter A Merkel, Gunnar Tómasson, Sara Monti, Kaitlin A Quinn, Leslie C Hassett, Loreto Carmona, Sofia Ramiro for the OMERACT Vasculitis Working Group
doi : 10.1093/rheumatology/keac175
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4603–4618
To systematically review the psychometric properties of outcome measurement instruments used in ANCA-associated vasculitis (AAV).
The SUMO components in rheumatoid arthritis
Qian Wu, Yao Jiang, Chongge You
doi : 10.1093/rheumatology/keac297
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4619–4630
Small ubiquitin-like modifier (SUMO) proteins can reversibly attach covalently or non-covalently to lysine residues of various substrates. The processes are named SUMOylation and de-SUMOylation, which maintain a dynamic balance in the physiological state, and are regulated by SUMO components. However, the dysregulation of components disturbs the balance and alters the functions of target proteins, which causes the occurrence of diseases.
Chilblains in immune-mediated inflammatory diseases: a review
Shirish Dubey, Nilay Joshi, Olivia Stevenson, Caroline Gordon, John A Reynolds
doi : 10.1093/rheumatology/keac231
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4631–4642
Chilblains were first described over a hundred years ago as cutaneous inflammatory lesions, typically on the digits, occurring on cold exposure. Chilblains can be primary, or secondary to a number of conditions such as infections, including COVID-19, and immune-mediated inflammatory disorders (IMIDs) with SLE being the commonest. Chilblain lupus erythematosus (CHLE) was first described in 1888 as cold-induced erythematous lesions before the terms ‘chilblains’ or ‘perniosis’ were coined. Diagnostic criteria exist for both chilblains and CHLE. Histopathologically, CHLE lesions show interface dermatitis with perivascular lymphocytic infiltrate.
Autoimmune disease and COVID-19: a multicentre observational study in the United Kingdom
Deepa J Arachchillage, Indika Rajakaruna, Charis Pericleous, Philip L R Nicolson, Mike Makris, Mike Laffan, the CA-COVID-19 Study Group
doi : 10.1093/rheumatology/keac209
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4643–4655
To establish the demographic characteristics, laboratory findings and clinical outcomes in patients with autoimmune disease (AD) compared with a propensity-matched cohort of patients without AD admitted with COVID-19 to hospitals in the UK.
All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study
Anne M Kerola, Amirhossein Kazemi, Silvia Rollefstad, Siri Lillegraven, Joseph Sexton, Grunde Wibetoe, Espen A Haavardsholm, Tore K Kvien, Anne Grete Semb
doi : 10.1093/rheumatology/keac210
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4656–4666
To explore mortality and causes of death among Norwegian patients with RA, PsA and axial spondyloarthritis (axSpA) compared with the general population by conducting a nationwide registry-based cohort study.
The impact of disease severity measures on survival in U.S. veterans with rheumatoid arthritis-associated interstitial lung disease
Rebecca Brooks, Joshua F Baker, Yangyuna Yang, Punyasha Roul, Gail S Kerr, Andreas M Reimold, Gary Kunkel, Katherine D Wysham, Namrata Singh, Deana Lazaro, Paul A Monach, Jill A Poole, Dana P Ascherman, Ted R Mikuls, Bryant R England
doi : 10.1093/rheumatology/keac208
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4667–4677
To determine whether RA and interstitial lung disease (ILD) severity measures are associated with survival in patients with RA-ILD.
Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
Sizheng Steven Zhao, Lianne Kearsley-Fleet, Ailsa Bosworth, Kath Watson, BSRBR-RA Contributors Group, Kimme L Hyrich
doi : 10.1093/rheumatology/keac190
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4678–4686
Whether patients with RA benefit from repeated trials of biologic or targeted synthetic DMARDs (b/tsDMARDs) after three or more attempts is unknown. We aimed to describe treatment outcomes in each line of b/tsDMARD therapy.
Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis
James M Gwinnutt, Sam Norton, Kimme L Hyrich, Mark Lunt, Bernard Combe, Nathalie Rincheval, Adeline Ruyssen-Witrand, Bruno Fautrel, Daniel F McWilliams, David A Walsh, Elena Nikiphorou, Patrick D W Kiely, Adam Young, Jacqueline R Chipping, Alex MacGregor, Suzanne M M Verstappen
doi : 10.1093/rheumatology/keac137
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4687–4701
To identify groups of people with RA with different disability trajectories over 10 years, despite comparable levels of inflammation.
Automated quantification system predicts survival in rheumatoid arthritis-associated interstitial lung disease
Ju Hyun Oh, Grace Hyun J Kim, Gary Cross, Joseph Barnett, Joseph Jacob, Seokchan Hong, Jin Woo Song
doi : 10.1093/rheumatology/keac184
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4702–4710
The prognosis of RA-associated interstitial lung disease (RA-ILD) is difficult to predict because of the variable clinical course. This study aimed to determine the prognostic value of an automated quantification system (AQS) in RA-ILD.
Retrospective longitudinal assessment of ultrasound gout lesions using the OMERACT semi-quantitative scoring system
Sara Nysom Christiansen, Mikkel Østergaard, Ole Slot, Viktoria Fana, Lene Terslev
doi : 10.1093/rheumatology/keac179
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4711–4721
The objectives of this study were (i) to evaluate the responsiveness of gout-specific US lesions representing urate deposition in patients receiving treat-to-target urate-lowering therapy using a binary and the OMERACT-defined semi-quantitative scoring systems; (ii) to determine the most responsive US measure for urate deposition and the optimal joint/tendon set for monitoring this.
Associations between syndesmophytes and facet joint ankylosis in radiographic axial spondyloarthritis patients on low-dose CT over 2 years
Rosalinde Stal, Alexandre Sepriano, Floris Alexander van Gaalen, Xenofon Baraliakos, Rosaline van den Berg, Monique Reijnierse, Juergen Braun, Robert B M Landewé, Désirée van der Heijde
doi : 10.1093/rheumatology/keac176
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4722–4730
In radiographic axial spondyloarthritis (r-axSpA), spinal damage manifests as syndesmophytes and facet joint ankylosis (FJA). We evaluated whether the presence of one lesion increased the risk of the other lesion.
Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials
Donald Stull, Sean O’Quinn, Betsy Williams, Stephanie Bean, Erik Schwetje, Gabriel Abreu, Raj Tummala
doi : 10.1093/rheumatology/keac138
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4731–4740
SLE significantly impairs health-related quality of life (HRQoL). In this post hoc analysis, structural equation modelling was used to examine the ‘causal cascade’ of interaction between anifrolumab, disease activity and patient-reported outcomes (PROs) in pooled data from the phase 3 TULIP-1 and TULIP-2 trials.
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis
Michael Nissen, Bénédicte Delcoigne, Daniela Di Giuseppe, Lennart Jacobsson, Merete Lund Hetland, Adrian Ciurea, Lucie Nekvindova, Florenzo Iannone, Nurullah Akkoc, Tuulikki Sokka-Isler, Karen Minde Fagerli, Maria Jose Santos, Catalin Codreanu, Manuel Pombo-Suarez, Ziga Rotar, Bjorn Gudbjornsson, Irene van der Horst-Bruinsma, Anne Gitte Loft, Burkhard M?ller, Herman Mann, Fabrizio Conti, Gozde Yildirim Cetin, Heikki Relas, Brigitte Michelsen, Pedro Avila Ribeiro, Ruxandra Ionescu, Carlos Sanchez-Piedra, Matija Tomsic, ?rni J?n Geirsson, Johan Askling, Bente Glintborg, Ulf Lindstr?m
doi : 10.1093/rheumatology/keac174
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4741–4751
Many axial spondylarthritis (axSpA) patients receive a conventional synthetic DMARD (csDMARD) in combination with a TNF inhibitor (TNFi). However, the value of this co-therapy remains unclear. The objectives were to describe the characteristics of axSpA patients initiating a first TNFi as monotherapy compared with co-therapy with csDMARD, to compare one-year TNFi retention and remission rates, and to explore the impact of peripheral arthritis.
Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus
Sharzad Emamikia, Shereen Oon, Alvaro Gomez, Julius Lindblom, Alexander Borg, Yvonne Enman, Eric Morand, David Grannas, Ronald F van Vollenhoven, Mandana Nikpour, Ioannis Parodis
doi : 10.1093/rheumatology/keac185
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4752–4762
To investigate the impact of remission and lupus low disease activity state (LLDAS) on health-related quality of life (HRQoL) in systemic lupus erythematosus.
Clinical integration of patient-reported outcome measures to enhance the care of patients with SLE: a multi-centre prospective cohort study
Shanthini Kasturi, Lori Lyn Price, Amy LeClair, Neena Patel, Shreya Shetty, Dina Sheira, Serena Weber, David Curtis, W Benjamin Nowell, Jane Salmon, Norma Terrin, Timothy E McAlindon, Lisa A Mandl
doi : 10.1093/rheumatology/keac200
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4763–4774
To assess the feasibility and impact of integrating electronic patient-reported outcome measures (PROMs) into the routine outpatient care of patients with SLE.
Muscle involvement in systemic lupus erythematosus: multimodal ultrasound assessment and relationship with physical performance
Andrea Di Matteo, Gianluca Smerilli, Edoardo Cipolletta, Richard J Wakefield, Rossella De Angelis, Anna Maria Risa, Fausto Salaffi, Sonia Farah, Catalina Villota-Eraso, Vincenzo Maccarrone, Emilio Filippucci, Walter Grassi
doi : 10.1093/rheumatology/keac196
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4775–4785
The objectives of this study were (1) to explore US findings for muscle mass, muscle quality and muscle stiffness in SLE patients and healthy subjects; (2) to investigate the relationship between the US muscle findings and physical performance in SLE patients and healthy subjects.
Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort
Elisabetta Zanatta, Dörte Huscher, Augusta Ortolan, Jérôme Avouac, Paolo Airò, Alexandra Balbir-Gurman, Elise Siegert, Marco Matucci Cerinic, Franco Cozzi, Gabriela Riemekasten, Anna-Maria Hoffmann-Vold, Oliver Distler, Armando Gabrielli, Stefan Heitmann, Nicolas Hunzelmann, Carlomaurizio Montecucco, Jadranka Morovic-Vergles, Camillo Ribi, Andrea Doria, Yannick Allanore, EUSTAR collaborators
doi : 10.1093/rheumatology/keac188
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4786–4796
To characterize patients with positive anti-topoisomerase I (ATA) in lcSSc.
Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study
Elizabeth Price, Michele Bombardieri, Alan Kivitz, Franziska Matzkies, Oksana Gurtovaya, Alena Pechonkina, Wendy Jiang, Bryan Downie, Anubhav Mathur, Afsaneh Mozaffarian, Neelufar Mozaffarian, J Eric Gottenberg
doi : 10.1093/rheumatology/keac167
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4797–4808
The aim of this study was to characterize the safety and efficacy of filgotinib, lanraplenib and tirabrutinib in patients with active SS.
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis
Elena Galli, Francesco Muratore, Pamela Mancuso, Luigi Boiardi, Chiara Marvisi, Giulia Besutti, Lucia Spaggiari, Massimiliano Casali, Annibale Versari, Paolo Giorgi Rossi, Carlo Salvarani
doi : 10.1093/rheumatology/keac125
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4809–4816
To evaluate the accuracy of PET/CT and of PET vascular activity score (PETVAS) in assessing disease activity and the ability of PETVAS in predicting relapses in a large single-centre cohort of patients with large vessel vasculitis (LVV).
Infection is associated with increased risk of MPO- but not PR3-ANCA-associated vasculitis
Jens Rathmann, Pavlos Stamatis, Göran Jönsson, Martin Englund, Mårten Segelmark, David Jayne, Aladdin J Mohammad
doi : 10.1093/rheumatology/keac163
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4817–4826
AA amyloidosis complicating cryopyrin-associated periodic syndrome: a study of 86 cases including 23 French patients and systematic review
François Rodrigues, Laurence Cuisset, Bérangère Cador-Rousseau, Irina Giurgea, Benedicte Neven, David Buob, Pierre Quartier, Eric Hachulla, Thierry Lequerré, Gérard Cam, Guilaine Boursier, Valérie Hervieu, Gilles Grateau, Sophie Georgin-Lavialle
doi : 10.1093/rheumatology/keac145
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4827–4834
Cryopyrin-associated periodic syndrome (CAPS) is a rare but treatable inherited autoinflammatory condition including familial cold autoinflammatory syndrome (FCAS), Muckle–Wells syndrome (MWS) and chronic infantile neurologic cutaneous articular syndrome (CINCA). Our objective was to describe the main features of CAPS AA amyloidosis (AA-CAPS) associated and the efficacy of IL-1 inhibitors in this indication.
Development and validation of the Kids Disability Screen for children with juvenile idiopathic arthritis: results from the CAPRI Registry
Kristin Houghton, Meghan McPherson, Nikola Surjanovic, Thomas Loughin, Roberta Berard, Jean-Phillipe Proulx-Gauthier, Gaëlle Chédeville, Dax Rumsey, Heinrike Schmeling, Nadia Luca, Nicole Johnson, Tommy Gerschman, Paivi Miettunen, Herman Tam, Lillian Lim, Kimberly Morishita, Rosie Scuccimarri, Johannes Roth, Ciaran Duffy, Lori Tucker, Brian M Feldman, Jaime Guzman, for the CAPRI Registry Investigators
doi : 10.1093/rheumatology/keac146
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4835–4844
The aim of this study was to develop and validate a brief disability screen for children with JIA, the Kids Disability Screen (KDS).
Investigating characteristics of idiopathic inflammatory myopathy flares using daily symptom data collected via a smartphone app
Alexander G S Oldroyd, Niels Steen Krogh, William G Dixon, Hector Chinoy
doi : 10.1093/rheumatology/keac161
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4845–4854
The objective of this study was to use daily data collected via a smartphone app for characterization of patient-reported and symptom-based (using an a priori definition) flares in an adult idiopathic inflammatory myopathy (IIM) cohort.
Statin-associated immune-mediated necrotizing myositis in Native Americans
Maheswari Muruganandam, Ahsan Iqbal, Eyerusalem B Akpan, Anthony C Dolomisiewicz, Yvonne M Waters, N Suzanne Emil, Sharon E Nunez, Matthew K McElwee, Frank X O’Sullivan, Roderick A Fields, Wilmer L Sibbitt, Jr.
doi : 10.1093/rheumatology/keac198
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4855–4862
Statin-associated immune-mediated necrotizing myopathy (IMNM) and idiopathic inflammatory myositis (IIM) are myopathies with overlapping features. This study compared the manifestations of IMNM to IIM in Native Americans.
Reliability assessment of the definition of ultrasound enthesitis in SpA: results of a large, multicentre, international, web-based study
Andrea Di Matteo, Edoardo Cipolletta, Giulia Maria Destro Castaniti, Gianluca Smerilli, Carla Airoldi, Sibel Zehra Aydin, Andrea Becciolini, Karina Bonfiglioli, Alessandra Bruns, Greta Carrara, Tomas Cazenave, Alessandro Ciapetti, Micaela Ana Cosatti, Juan José de Agust?n, Marco Di Carlo, Eleonora Di Donato, Luca Di Geso, Emine Duran, Ashley Elliott, Cristina Estrach, Bayram Farisogullar?, Alessia Fiorenza, Daniela Fodor, Alessandra Gabba, Cristina Hern?ndez-D?az, Feng Huang, Jana Hurnakova, Ling Li, Diogo Jesus, Omer Karadag, Maria Victoria Martire, Marco Massarotti, Xabier Michelena, Alice Andreea Musca, Jagdish Nair, Tadashi Okano, Ioannis Papalopoulos, Marcos Rosemffet, Jo?o Rovisco, Davide Rozza, Fausto Salaffi, Iulia Satulu, Crescenzio Scioscia, Carlo Alberto Scirè, Fei Sun, Maria-Magdalena Tamas, Shun Tanimura, Lucio Ventura-Rios, Paraksevi V Voulgari, Florentin Ananu Vreju, Gentiana Vukatana, Ernest Wong, Jinshui Yang, Johana Zacariaz Hereter, Anna Zanetti, Walter Grassi, Emilio Filippucci
doi : 10.1093/rheumatology/keac162
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4863–4874
To investigate the reliability of the OMERACT US Task Force definition of US enthesitis in SpA.
Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD
Yasuyuki Todoroki, Satoshi Kubo, Kazuhisa Nakano, Yusuke Miyazaki, Masanobu Ueno, Yurie Satoh-Kanda, Ryuichiro Kanda, Ippei Miyagawa, Kentaro Hanami, Keisuke Nakatsuka, Kazuyoshi Saito, Shingo Nakayamada, Yoshiya Tanaka
doi : 10.1093/rheumatology/keac165
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4875–4884
MCTD manifests with microvasculopathy and overlapping clinical features of SLE, SSc and idiopathic inflammatory myopathies (IIM). The aim of this study was to investigate the clinical significance of microvasculopathy in patients with MCTD using nailfold videocapillaroscopy (NVC).
Treatment of childhood-onset Takayasu arteritis: switching between anti-TNF and anti-IL-6 agents
Seher Sener, Ozge Basaran, Ummusen Kaya Akca, Erdal Atalay, Muserref Kasap Cuceoglu, Zeynep Balik, Emil Aliyev, Yagmur Bayindir, Ezgi Deniz Batu, Tuncay Hazirolan, Yelda Bilginer, Seza Ozen
doi : 10.1093/rheumatology/keac149
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4885–4891
Biologics are new treatment alternatives in Takayasu arteritis (TA), although data in childhood are limited. The aim of this study was to share our experience in seven childhood-onset TA patients who received a TNF-α inhibitor (adalimumab) or an IL-6 receptor inhibitor (tocilizumab) and the effect of switching therapy.
An ultrasound negative for subclinical synovitis in arthralgia patients: is it helpful in identifying those not developing arthritis? A longitudinal study in four arthralgia cohorts
Cleo Rogier, Giulia Frazzei, Marion C Kortekaas, Marloes Verstappen, Sarah Ohrndorf, Elise van Mulligen, Ronald F van Vollenhoven, Dirkjan van Schaardenburg, Pascal H P de Jong, Annette H M van der Helm-van Mil
doi : 10.1093/rheumatology/keac239
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4892–4897
To investigate the negative predictive value (NPV) of musculoskeletal US (MSUS) in arthralgia patients at risk for developing inflammatory arthritis.
Dual-energy CT assessment of rapid monosodium urate depletion and bone erosion remodelling during pegloticase plus methotrexate co-therapy
Nicola Dalbeth, Fabio Becce, John K Botson, Lin Zhao, Ada Kumar
doi : 10.1093/rheumatology/keac173
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4898–4904
Pegloticase rapidly lowers serum urate in uncontrolled/refractory gout patients, with ≥1 tophus resolution in 70% of pegloticase responders and 28% of non-responders. Dual-energy computed tomography (DECT) non-invasively detects MSU deposition, including subclinical deposition, quantifies MSU volumes and depicts bone erosions. This report presents DECT findings in MIRROR open-label trial participants receiving pegloticase+MTX co-therapy.
Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab
Jack Arnold, Shouvik Dass, Sarah Twigg, Colin H Jones, Ben Rhodes, Peter Hewins, Mithun Chakravorty, Phil Courtney, Michael Ehrenstein, Md Yuzaiful Md Yusof, Edward M Vital
doi : 10.1093/rheumatology/keac150
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4905–4909
Secondary inefficacy with infusion reactions and anti-drug antibodies (secondary non-depletion nonresponse, 2NDNR) occurs in 14% of SLE patients receiving repeated rituximab courses. We evaluated baseline clinical characteristics, efficacy and safety of obinutuzumab, a next-generation humanized type-2 anti-CD20 antibody licensed for haematological malignancies in SLE patients with 2NDNR to rituximab.
Osteophytes’ position in subjects with DISH and right-sided aorta: verification of the ‘aortic pulsation protective effect’ theory
Masha Gliner-Ron, Eyal Bercovich, Amir Herman, Merav Lidar, Daniela Militianu, Iris Eshed
doi : 10.1093/rheumatology/keac183
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4910–4914
To validate in a large cohort with right-sided aorta the theory that thoracic right-sided flowing osteophytes in DISH results from a ‘protective’ effect of the pulsating descending left-sided thoracic aorta.
Associations of the MUC5B promoter variant with timing of interstitial lung disease and rheumatoid arthritis onset
Gregory McDermott, Ritu Gill, Staci Gagne, Suzanne Byrne, Weixing Huang, Jing Cui, Lauren Prisco, Alessandra Zaccardelli, Lily Martin, Vanessa L Kronzer, Matthew Moll, Michael H Cho, Nancy Shadick, Paul F Dellaripa, Tracy Doyle, Jeffrey A Sparks
doi : 10.1093/rheumatology/keac152
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4915–4923
To investigate the associations of the common MUC5B promoter variant with timing of RA-associated interstitial lung disease (RA-ILD) and RA onset.
Elevations in adipocytokines and mortality in rheumatoid arthritis
Joshua F Baker, Bryant R England, Michael D George, Katherine Wysham, Tate Johnson, Gary Kunkel, Brian Sauer, Bartlett C Hamilton, Carlos D Hunter, Michael J Duryee, Paul Monach, Gail Kerr, Andreas Reimold, Rui Xiao, Geoff M Thiele, Ted R Mikuls
doi : 10.1093/rheumatology/keac191
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4924–4934
This study assessed whether circulating levels of adiponectin and leptin are associated with higher mortality in patients with RA.
Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy
Megan Sutcliffe, Nisha Nair, James Oliver, Ann W Morgan, John D Isaacs, Anthony G Wilson, Suzanne M M Verstappen, Sebastien Viatte, Kimme L Hyrich, Andrew P Morris, Anne Barton, Darren Plant
doi : 10.1093/rheumatology/keac204
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4935–4944
No reliable biomarkers to predict response to TNF inhibitors (TNFi) in RA patients currently exist. The aims of this study were to replicate changes in gene co-expression modules that were previously reported in response to TNFi therapy in RA; to test if changes in module expression are specific to TNFi therapy; and to determine whether module expression transitions towards a disease-free state in responding patients.
Advanced neural networks for classification of MRI in psoriatic arthritis, seronegative, and seropositive rheumatoid arthritis
Lukas Folle, Sara Bayat, Arnd Kleyer, Filippo Fagni, Lorenz A Kapsner, Maja Schlereth, Timo Meinderink, Katharina Breininger, Koray Tascilar, Gerhard Krönke, Michael Uder, Michael Sticherling, Sebastian Bickelhaupt, Georg Schett, Andreas Maier, Frank Roemer, David Simon
doi : 10.1093/rheumatology/keac197
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4945–4951
To evaluate whether neural networks can distinguish between seropositive RA, seronegative RA, and PsA based on inflammatory patterns from hand MRIs and to test how psoriasis patients with subclinical inflammation fit into such patterns.
Defining imaging sub-phenotypes of psoriatic arthritis: integrative analysis of imaging data and gene expression in a PsA patient cohort
Lihi Eder, Quan Li, Sara Rahmati, Proton Rahman, Igor Jurisica, Vinod Chandran
doi : 10.1093/rheumatology/keac078
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4952–4961
To define imaging sub-phenotypes in patients with PsA; determine their association with whole blood gene expression and identify biological pathways characterizing the sub-phenotypes.
Soluble LILRA3 is aberrantly expressed in antiphospholipid syndrome (APS) and is a potential marker of thrombotic APS
Hongjiang Liu, Chun Li, Hui Shi, Yixue Guo, Yundi Tang, Chen Chen, Zhen Zhao, Claire K Hoy, Srilakshmi Yalavarthi, Gabriel Figueroa-Parra, Ali Duarte-Garcia, Yu Zuo, Zhanguo Li, Jason S Knight, Jianping Guo
doi : 10.1093/rheumatology/keac192
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4962–4974
Leucocyte immunoglobulin-like receptor A3 (LILRA3) belongs to a family of leucocyte receptors. Our previous study reported LILRA3 transcripts were markedly upregulated in neutrophils from patients with APS. We undertook this study to investigate clinical implications of LILRA3 in APS and its potential role in APS-associated thrombosis.
Soluble interleukin-2 receptor serum levels facilitate prediction of relapses in subgroups of patients with juvenile idiopathic arthritis
Linda Ziegler, Sabrina Fuehner, Christoph Kessel, Claas Hinze, Jens Klotsche, Martina Niewerth, Kirsten Minden, Dirk Foell
doi : 10.1093/rheumatology/keac178
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4975–4984
JIA is characterised by a chronic disease course. Once patients achieve a state of inactive disease, there are no established biomarkers to predict the further course of inflammation for these patients. Therefore, the purpose of this study was to quantify serum biomarkers during quiescent disease to evaluate their use in identifying JIA patients at risk for future disease flare.
Anti-citrullinated protein antibody specificities and pulmonary fibrosis in relation to genetic loci in early rheumatoid arthritis
Mikael Brink, Lotta Ljung, Monika Hansson, Johan Rönnelid, Rickard Holmdahl, Karl Skriner, Guy Serre, Lars Klareskog, Solbritt Rantapää-Dahlqvist
doi : 10.1093/rheumatology/keac280
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4985–4990
Pulmonary manifestations in RA are common comorbidities, but the underlying mechanisms are largely unknown. The added value of a multiplex of ACPA and genetic risk markers was evaluated for the development of pulmonary fibrosis (PF) in an inception cohort.
ELISA, protein immunoprecipitation and line blot assays for anti-TIF1-gamma autoantibody detection in cancer-associated dermatomyositis
Sandra Selickaja, Angeles S Galindo-Feria, Lara Dani, Tsuneyo Mimori, Johan Rönnelid, Marie Holmqvist, Ingrid E Lundberg, Paulius Venalis
doi : 10.1093/rheumatology/keac288
Rheumatology, Volume 61, Issue 12, December 2022, Pages 4991–4996
Anti�TIF1-gamma autoantibodies can be detected with immunoprecipitation (IP), line blot (LB) and ELISA. We compared assay performance in patients with DM and the potential of these assays to detect anti-TIF1-gamma positive cancer-associated DM (CADM).
Erratum to: Parvovirus B19 induces cellular senescence in human dermal fibroblasts: putative role in systemic sclerosis-associated fibrosis
Rosaria Arvia, Krystyna Zakrzewska, Lisa Giovannelli, Sara Ristori, Elena Frediani, Mario Del Rosso, Alessandra Mocali, Maria A Stincarelli, Anna Laurenzana, Gabriella Fibbi, Francesca Margheri
doi : 10.1093/rheumatology/keab936
Rheumatology, Volume 61, Issue 12, December 2022, Page 4997
Correction to: Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration
Bénédicte Delcoigne, Sella Aarrestad Provan, Hilde Berner Hammer, Daniela Di Giuseppe, Thomas Frisell, Bente Glintborg, Gerdur Grondal, Bjorn Gudbjornsson, Merete Lund Hetland, Brigitte Michelsen,Dan Nordstr?m, Heikki Relas, Johan Askling
doi : 10.1093/rheumatology/keac151
Rheumatology, Volume 61, Issue 12, December 2022, Page 4998
Rheumatological diseases in patients with primary hyperparathyroidism
Valeria Erazo-MartÃnez, José Alejandro-Posso, Carolina MedellÃn, Michiko Kaimoto, Carlos A Cañas, Gabriel J Tobón
doi : 10.1093/rheumatology/keac303
Rheumatology, Volume 61, Issue 12, December 2022, Pages e358–e359
Safety and immunogenicity of fifth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series
Mayan S Teles, Caoilfhionn M Connolly, Rachel Wallwork, Sarah Frey, Teresa Po-Yu Chiang, Jennifer L Alejo, Jemima Albayda, Lisa Christopher-Stine, Dorry L Segev, William A Werbel, Julie J Paik
doi : 10.1093/rheumatology/keac370
Rheumatology, Volume 61, Issue 12, December 2022, Pages e360–e362
Risk of systemic vasculitis following mRNA COVID-19 vaccination: a pharmacovigilance study
Camille Mettler, Benjamin Terrier, Jean-Marc Treluyer, Laurent Chouchana
doi : 10.1093/rheumatology/keac323
Rheumatology, Volume 61, Issue 12, December 2022, Pages e363–e365
A rare onset in tumour necrosis factor receptor–associated periodic syndrome: recurrent macrophage activation syndrome triggered by COVID-19 infection
Şengül Çağlayan, Kadir Ulu, Mustafa Çakan, Betül Sözeri
doi : 10.1093/rheumatology/keac362
Rheumatology, Volume 61, Issue 12, December 2022, Pages e366–e367,
Rare meets rarer: anti-synthetase syndrome in a patient with facio-scapulo-humeral muscular dystrophy
Larissa Valor-Méndez, Bernhard Manger, Martin Winterholler, Georg Schett, Mattias Türk, Johannes Knitza
doi : 10.1093/rheumatology/keac328
Rheumatology, Volume 61, Issue 12, December 2022, Pages e368–e370
Novel genetic mutation in myositis-variant of VEXAS syndrome
James S Topilow, Daniela Ospina Cardona, David B Beck, Marcela A Ferrada, Zsuzsanna H McMahan, Julie J Paik
doi : 10.1093/rheumatology/keac356
Rheumatology, Volume 61, Issue 12, December 2022, Pages e371–e373
VEXAS syndrome complicated with severe infection
Toshimasa Shimizu, Hiroyuki Ide, Yoshika Tsuji, Tomohiro Koga, Atsushi Kawakami
doi : 10.1093/rheumatology/keac364
Rheumatology, Volume 61, Issue 12, December 2022, Pages e374–e376
Comment on: Muscle involvement in systemic lupus erythematosus: multimodal ultrasound assessment and relationship with physical performance
Ruifeng Liu, Yu Xia
doi : 10.1093/rheumatology/keac270
Rheumatology, Volume 61, Issue 12, December 2022, Pages e377–e378
Comment on: Muscle involvement in systemic lupus erythematosus: multimodal ultrasound assessment and relationship with physical performance: reply
Andrea Di Matteo, Gianluca Smerilli, Edoardo Cipolletta, Richard J Wakefield, Emilio Filippucci, Walter Grassi
doi : 10.1093/rheumatology/keac268
Rheumatology, Volume 61, Issue 12, December 2022, Pages e379–e380
Comment on: Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD
Katsumasa Oe, Shogo Matsuda, Takuya Kotani, Tohru Takeuchi
doi : 10.1093/rheumatology/keac291
Rheumatology, Volume 61, Issue 12, December 2022, Pages e381–e382
IRF6 mutation in systemic sclerosis: innocent bystander or contributing factor?
Jan-Gerd Rademacher, Peter Korsten
doi : 10.1093/rheumatology/keac414
Rheumatology, Volume 61, Issue 12, December 2022, Page e383
Smoldering giant cell arteritis in a coronary artery
Mahmut Kaymakci, Mohanad Elfishawi, Mariam P Alexander, Matthew J Koster, Kenneth J Warrington
doi : 10.1093/rheumatology/keac321
Rheumatology, Volume 61, Issue 12, December 2022, Pages e384–e385
Phalangeal involvement as an initial presentation in SAPHO syndrome
Xia Wu, Yihan Cao, Chen Li
doi : 10.1093/rheumatology/keac310
Rheumatology, Volume 61, Issue 12, December 2022, Pages e386–e387
